Industries > Pharma > Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

PUBLISHED: 19 December 2018
PAGES: 160
PRODUCT CODE: PHA0349

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

The global asthma & COPD market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2019-2029

• Profiles of the leading 20 asthma & COPD companies:
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• GlaxoSmithKline
• Lallemand Pharma International
• Merck
• MundiPharma
• Novartis
• Pulmatrix
• Roche
• Sanofi/Regeneron
• Sunovion
• Teva
• Theravance Biopharma|Mylan Inc.
• Vectura Group plc
• Verona Pharma plc

Top 20 Asthma & COPD Companies 2019-2029

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2019-2029
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series : Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Latest Pharma news

Visiongain Publishes Gene Amplification Technologies Market Report 2023-2033

The Gene Amplification Technologies market was valued at US$4,587 million in 2022 and is projected to grow at a CAGR of 9.8% during the forecast period 2023-2033.

05 December 2022

READ

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

READ

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

READ

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

READ